Biotech week ahead, Feb 4

The earnings season hasn’t panned out well for pharma companies, with Amgen, Inc. AMGN 0.02%, Novartis AG NVS 0.16% and Illumina, Inc. ILMN 1.08% reporting either disappointing results or a bleak guidance.

Even as the earnings news flow picks up pace, here are a few catalysts a biotech investor should focus on in the unfolding week.

Conferences

• 15th Annual WORLDSymposium – Feb. 4–8, in Orlando, Florida
• 12th annual Congress of the European Association For Hemophilia and Allied Disorders (EAHAD) – Feb. 6-8, in Prague, Czech Republic

Clinical Trial Results

Sienna Biopharmaceuticals Inc SNNA 4.85% is due to release Phase 3 data for SNA-001, its investigational therapy used for the reduction of light-pigmented hair in early February.

Avrobio Inc AVRO 7.95% is scheduled to release an update on Phase 1 study and two-year data for first patient treated with Fabry disease candidate AVR-RD-01 at the WORLDSymposium Wednesday, Feb. 6.

Protalix Biotherapeutics Inc PLX 13.85% will release Phase 3 pharmacokinetic data for Pegunigalsidase alfa, its Fabry disease treatment candidate, at the WORLDSymposium Thursday, Feb. 7

Sangamo Therapeutics Inc SGMO 6.67% is set to release Phase 1/2 preliminary safety and biochemical measurements for SB-318, its treatment candidate for MPS Type 1, at the WORLDSymposium Thursday, Feb. 7. The company will also release biochemical and safety data for SB-913, its MPS Type 2 treatment candidate, at the symposium the same day.

Catalyst Biosciences Inc CBIO 4.78% is due to present Phase 2 data for its hemophilia treatment candidate Marzeptacog alfa at the EAHAD annual Congress to be held between Feb. 6 and Feb. 8.

Earnings

Monday, Feb. 4

• Alexion Pharmaceuticals, Inc. ALXN 2.7% (before the market open)
• Gilead Sciences, Inc. GILD 0.07% (after the market close)

Tuesday, Feb. 5

• Array Biopharma Inc ARRY 2.84%
• Neurocrine Biosciences, Inc. NBIX 0.03% (after the close)

Wednesday, Feb. 6

• Boston Scientific Corporation BSX 0.52% (before the market open)
• Regeneron Pharmaceuticals Inc REGN 0.24% (before the market open)
• Enanta Pharmaceuticals Inc ENTA 3.1% (after the close)

Thursday, Feb. 7

• Arrowhead Pharmaceuticals Inc ARWR 1.2% (after the close)
• Twist Bioscience Corp TWST 0.56% (after the close)
• Organovo Holdings Inc ONVO 0.99% (after the close)
• Seattle Genetics, Inc. SGEN 0.77% (after the close)
• Ligand Pharmaceuticals Inc. LGND 1.89% (after the close)

Friday. Feb. 8

• ImmunoGen, Inc. IMGN (before the market open)

See Also: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

IPO

California-based clinical-stage biotech Alector, which develops treatments for neurodegeneration, is set to offer 9.25 million shares in an IPO, to be priced between $18 and $20. The company intends to list the shares on the Nasdaq under the ticker symbol ALEC.

Harpoon Therapeutics, an immuno-oncology company, plans to offer 5.4 million shares in an IPO, with the shares to be priced in the $13-$15 range. The shares will be listed om the Nasdaq under the ticker symbol HARP.

Gossamer Bio is planning to offer 14.38 million shares in an IPO. The company that develops therapeutics for immunology, cancer and inflammation is likely to price the shares at $16. The shares will be listed om the Nasdaq under the ticker symbol GOSS.

https://www.benzinga.com/general/biotech/19/02/13067087/the-week-ahead-in-biotech-conferences-clinical-trials-earnings-and-ip